CARCINOMA-EMBRYONIC antigen (CEA) was first identified by Gold & Freedman (1965) in colorectal tumours and to a lesser extent in normal large bowel and foetal tissue. It has since become clear that this glycoprotein is present in other tumours, and shows much heterogeneity particularly in its carbohydrate constitution (Coligan et al., 1972; Banjo et al., 1974) . Potter et al. (1978) identified a CEArelated substance which they called JCL-CEA, but after further characterization renamed it Tennessee antigen or Tennagen. In addition to the chemical characteristics of this substance, a haemagglutinationinhibition method of assay for human serum was described and a wide range of values in normal subjects, tumourbearing and non-tumour-bearing patients was reported. The results indicated that more than 900 0of cancer patients gave values in excess of 5.5 u/ml serum in the test, including those with Dukes' Stage A colorectal cancer. Conversely, little more than 5% of healthy subjects gave similarlv raised values, and 5-5 u/ml was therefore taken as the upper limit of normal.
In a wide variety of non-malignant conditions Tennagen was found to be raised in a high proportion of patients, but always falling substantially short of 9000. The Tennagen assay compared favourably with the CEA radioimmunoassay in these authors' hands.
Further reports (Potter et al., 1979) have evaluated the assay in terms of initial diagnosis, staging and serial monitoring. It was concluded that the assay was valuable not only in diagnosis but also in monitoring recurrence after surgical removal or other therapy. A recent report (Oehr et al., 1981) has evaluated Tennagen, CEA and Tissue Polypeptide Antigen in patients with bladder or testes cancer, where each antigen was found to be raised in 5000 of cases regardless of stage, but no controls were included. The subject is reviewed in detail by Seidenberger (1980 
SUBJECTS
The "normal" subjects used in this study were drawn from the staff of the Charing Cross Hospital and other volunteers. Care was taken to exclude staff in any way involved with cancer patients or who handled tumour material. Previous experience in this laboratory with other tests (Browne et al., 1980) has shown this to be a necessary precaution.
Nevertheless the word '"normal" is not strictly accurate when discussing the healthy volunteers tested in this study, although 5/22 were not hospital staff. The patients were attending Charing Cross Hospital, St Mark's Hospital, London, Birmingham General Hospital and Llandudno General Hospital, Wales. The sex, age and diagnosis of the groups studied are indicated in Table I .
For the purpose of this test cancer patients were grouped as "active" with clinical or radiological evidence of disease or a "clinical remission" with no clinical or radiological evidence of disease.
Staging of patients with colorectal cancer was based on clinical, radiological and laparotomy evidence. Blood samples for assessment in relation to disease stage according to Dukes' criteria (1937) , were obtained on the day staging was ascertained.
METHODS
The method as described in the "Lancer Directions Manual" was followed with scrupulous care.
Blood (5-10 ml) was obtained by venepuncture and transferred from the syringe to a glass container, allowed to clot, centrifuged and the serum transferred to a sterile glass bijou bottle for storage at -20°C. Where blood had been taken in other centres, it was ascertained that this procedure had been followed. For extraction, 1 0 ml of serum was thawed at room temperature and control sera were not within the limit indicated in the test kit. The limits given are: Level I (2-7 u/ml), Level II (3-9-7-7 u/ml) and Level III (10-9-15-5 u/ml). It was decided that the test should be invalidated if even one control result fell outside the required limits. This only happened on 3 occasions during the course of the study and could be attributed to vibration each time.
Tennagen values are quoted as u/ml. Values over 5-5 u/ml were regarded as positive.
CEA was measured by double-antibody radioimmunoassay (Searle et al., 1974) and values up to 10 ng/ml were obtained in normal subjects or non-malignant disease.
RESULTS
Tests were performed on 22 normal subjects, 29 patients with various nonmalignant diseases and 116 patients with a histological diagnosis of cancer.
The instruction manual stated that the frozen dialysed extract could be thawed and frozen repeatedly without affecting the results. Since it is sometimes necessary to repeat tests we decided to evaluate this claim. Accordingly we set up repeat tests at varying intervals after the first test, using the previously tested (and hence twice thawed) aliquot and an "undisturbed" aliquot. Fig. 1 This low sensitivity of the test may be explained by our finding (see Table III ) in 3/8 cases of colorectal cancer, that whereas the pre-operative serum level of Tennagen was within the previously prescribed upper normal limit of 5-5 u/ml, the post-operative 8th day sample had a raised level. In 3 further patients the pre-operative level was raised but the post-operative value was higher still. It seems possible that surgical manipulations caused a release of antigen into the blood.
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It remains to be determined whether surgery for non-malignant disease produces a transient increase in Tennagen values, but clearly the interval between surgery and sampling for Tennagen values can affect the results.
In this small series of follow-up studies there has been only one clinical relapse. There was a rise in both Tennagen and CEA values at the time of relapse and both values rose in parallel before death. This patient (N.M. in Fig. 5 ) had advanced metastatic disease and was there- , not accompanied by a rise in CEA values. In a further patient (J.T.) the rise in Tennagen was out of phase with that in CEA. It should be noted in this context that Potter et al. (1978) found somewhat raised values in patients with non-malignant disorders, which raises the possibility of Tennagen being an inflammatory rather than a neoplastic antigen. It may be relevant that patient M.M. had some inflammatory problems, with a bowel colostomy 1 week before her transient rise in Tennagen. On this small series it would be premature to evaluate the Tennagen assay as a means for monitoring disease progress. Further study of this monitoring application is needed.
Our percentage of raised values in benign disorders is considerably more than published values, and in malignant disease, considerably less, so in our hands the specificity of the Tennagen test, as at present constituted, appears to fall below the level for optimal clinical utility as a general test for cancer.
